martes, 30 de octubre de 2018

Pharmaceutical policy issues :: Israel Journal of Health Policy Research

Pharmaceutical policy issues

Israel Journal of Health Policy Research



Pharmaceutical policy issues

  1. Content Type:Commentary

    Nissanholtz-Gannot and Yenkellevich (NGY) explore the impact of a 2010 amendment to the Israeli National Health Insurance Law that requires annual reporting of payments from pharmaceutical companies (PCs) to d...
    Authors:Ronen Avraham and Charles Silver
    Citation:Israel Journal of Health Policy Research 2018 7:25
    Published on: 
    The original article was published in Israel Journal of Health Policy Research 2017 6:45
  2. Content Type:Commentary

    Non-adherence to medication regimens is a major issue that can negatively impact patient health and wastes health care system resources. This commentary considers whether approaches to strategies undertaken in...
    Authors:Nigel S. B. Rawson
    Citation:Israel Journal of Health Policy Research 2017 6:63
    Published on: 
    The original article was published in Israel Journal of Health Policy Research 2017 6:50
  3. Content Type:Integrative Article

    The correct and rational use of medications can have a positive direct impact on disease outcomes, as well on the utilization of the health system resources. Unfortunately, 50% of the patients do not take thei...
    Authors:Eyal Schwartzberg, Zohar Barnett-Itzhaki, Itamar Grotto and Eli Marom
    Citation:Israel Journal of Health Policy Research 2017 6:50
    Published on: 
    The Commentary to this article has been published in Israel Journal of Health Policy Research 2017 6:63
  4. Content Type:Integrative Article

    In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During ...
    Authors:Nitzan Avisar, Yael Heller, Clara Weil, Aviva Ben-Baruch, Shani Potesman-Yona, Ran Oren, Gabriel Chodick, Varda Shalev and Nachman Ash
    Citation:Israel Journal of Health Policy Research 2017 6:46
    Published on: 
    The Commentary to this article has been published in Israel Journal of Health Policy Research 2018 7:3
  5. Content Type:Original Research Article

    The Israeli National Health Insurance Law was amended in 2010 to require the disclosure of payments above 2500 NIS from pharmaceutical companies (PCs) to medical personnel and organizations. We examined if the...
    Authors:Rachel Nissanholtz-Gannot and Ariel Yankellevich
    Citation:Israel Journal of Health Policy Research 2017 6:45
    Published on: 
    The Commentary to this article has been published in Israel Journal of Health Policy Research 2018 7:25
  6. Content Type:Original Research Article

    Due to the limited safety data available at the time that a new medication is first marketed, it is essential to continue the collection and monitoring of safety data about adverse drug reactions (ADRs) during...
    Authors:Eyal Schwartzberg, Matitiahu Berkovitch, Dorit Dil Nahlieli, Joseph Nathan and Einat Gorelik
    Citation:Israel Journal of Health Policy Research 2017 6:29
    Published on: 
  7. Content Type:Commentary

    The recent IJHPR article by Schwartzberg and colleagues presents new data on the growing problem of prescription drug shortages. Resolving shortages typically involves many participants: government, industry, ...
    Authors:Eric Efraim Katz
    Citation:Israel Journal of Health Policy Research 2017 6:28
    Published on: 
    The original article was published in Israel Journal of Health Policy Research 2017 6:17
  8. Content Type:Original Research Article

    Pharmaceutical drug shortages (DSs) are a global problem which presents challenges to countries around the world. Shortages of pharmaceutical products may have a direct detrimental impact on public health and ...
    Authors:Eyal Schwartzberg, Denize Ainbinder, Alla Vishkauzan and Ronni Gamzu
    Citation:Israel Journal of Health Policy Research 2017 6:17
    Published on: 
    The Commentary to this article has been published in Israel Journal of Health Policy Research 2017 6:28
  9. Content Type:Commentary

    Pharmaceutical disposal and the environmental fate of medication metabolites directly impacts the public’s health in two significant ways: accidental medication ingestion of pharmaceuticals that were not dispo...
    Authors:Eric D. Amster
    Citation:Israel Journal of Health Policy Research 2016 5:58
    Published on: 
    The original article was published in Israel Journal of Health Policy Research 2016 5:48
  10. Content Type:Integrative Article

    Large amounts of expired and unused medications accumulate in households. This potentially exposes the public to hazards due to uncontrolled use of medications. Most of the expired or unused medications that a...
    Authors:Zohar Barnett-Itzhaki, Tamar Berman, Itamar Grotto and Eyal Schwartzberg
    Citation:Israel Journal of Health Policy Research 2016 5:48
    Published on: 
    The Commentary to this article has been published in Israel Journal of Health Policy Research 2016 5:58
  12. Content Type:Original Research Article

    Modern drug therapy accounts for a major share of health expenditure and challenges public provider resources. The objective of our study was to compare drug expenditure trends for ten major drug classes over ...
    Authors:Yossef Lomnicky, Daniel Kurnik, Ronen Loebstein, Itzhak Katzir, Janet Vesterman-Landes and Nava Siegelmann-Danieli
    Citation:Israel Journal of Health Policy Research 2016 5:37
    Published on: 
  13. Content Type:Commentary

    Individuals, families, health plans and governments are struggling with the growing importance of managing chronic, non-communicable diseases. People in many countries are living longer and thus are facing man...
    Authors:Donald F. Downing
    Citation:Israel Journal of Health Policy Research 2015 4:62
    Published on: 
  14. Content Type:Integrative Article

    Pharmacy prescribing policy in Israel has been negotiated and changed in recent years in order to improve patient treatment and access to medicines, and reduce national health insurance costs by allowing pharm...
    Authors:Hila Yariv
    Citation:Israel Journal of Health Policy Research 2015 4:49
    Published on: 
  15. Content Type:Commentary

    The ageing of the population across developed countries and beyond has increased the importance of examining multi-morbidity. The recent paper by Arbelle et al. [Isr J of Health Policy Res. 2014;3:29] on multi...
    Authors:Raphael Wittenberg
    Citation:Israel Journal of Health Policy Research 2015 4:1
    Published on: 
  17. Content Type:Integrative Article

    This article focuses on governance of the pharmaceutical sector in Israel. It traces the relationships between the state, industry, and sick funds from before the establishment of National Health Insurance (NH...
    Authors:Philip Sax
    Citation:Israel Journal of Health Policy Research 2014 3:16
    Published on: 
  19. Content Type:Original Research Article

    Deciding which health technologies to fund involves confronting some of the most difficult choices in medicine. As for other countries, the Israeli health system is faced each year with having to make these di...
    Authors:Ofra Golan and Paul Hansen
    Citation:Israel Journal of Health Policy Research 2012 1:44
    Published on: 
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)